Edward Copelan

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. pmc Sustained disease-free survival achieved with withdrawal of immunosuppression after rapid relapse of myelodysplastic syndrome following myeloablative allogeneic hematopoietic transplantation: a case report
    Betty K Hamilton
    Bone Marrow Transplant Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Med Case Rep 7:18. 2013
  2. pmc Histone H4 acetylation by immunohistochemistry and prognosis in newly diagnosed adult acute lymphoblastic leukemia (ALL) patients
    Anjali S Advani
    Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, The Cleveland Clinic, Cleveland, OH, USA
    BMC Cancer 10:387. 2010
  3. ncbi A scheme for defining cause of death and its application in the T cell depletion trial
    Edward Copelan
    Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Biol Blood Marrow Transplant 13:1469-76. 2007
  4. doi Late mortality and relapse following BuCy2 and HLA-identical sibling marrow transplantation for chronic myelogenous leukemia
    Edward A Copelan
    Department of Hematologic Oncology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Biol Blood Marrow Transplant 15:851-5. 2009
  5. doi A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma
    E Copelan
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA
    Bone Marrow Transplant 43:101-5. 2009
  6. doi Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma
    Brian T Hill
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Leuk Lymphoma 52:986-93. 2011
  7. doi Elevated ferritin is associated with relapse after autologous hematopoietic stem cell transplantation for lymphoma
    Anuj Mahindra
    Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Biol Blood Marrow Transplant 14:1239-44. 2008
  8. doi The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls
    Brian T Hill
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute Quantitative Health Sciences, Cleveland Clinic Lerner Research Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Br J Haematol 152:561-9. 2011
  9. doi Race and intensity of post-remission therapy in acute myeloid leukemia
    Anna K Brady
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
    Leuk Res 35:346-50. 2011
  10. doi Nonmyeloablative second transplants are associated with lower nonrelapse mortality and superior survival than myeloablative second transplants
    Brian T Hill
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Biol Blood Marrow Transplant 16:1738-46. 2010

Collaborators

Detail Information

Publications23

  1. pmc Sustained disease-free survival achieved with withdrawal of immunosuppression after rapid relapse of myelodysplastic syndrome following myeloablative allogeneic hematopoietic transplantation: a case report
    Betty K Hamilton
    Bone Marrow Transplant Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Med Case Rep 7:18. 2013
    ..abstract:..
  2. pmc Histone H4 acetylation by immunohistochemistry and prognosis in newly diagnosed adult acute lymphoblastic leukemia (ALL) patients
    Anjali S Advani
    Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, The Cleveland Clinic, Cleveland, OH, USA
    BMC Cancer 10:387. 2010
    ....
  3. ncbi A scheme for defining cause of death and its application in the T cell depletion trial
    Edward Copelan
    Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Biol Blood Marrow Transplant 13:1469-76. 2007
    ..This algorithm promotes consistent assignment of primary and contributing CODs for patients with leukemia or lymphoma who expire after myeloablative allogeneic HSCT...
  4. doi Late mortality and relapse following BuCy2 and HLA-identical sibling marrow transplantation for chronic myelogenous leukemia
    Edward A Copelan
    Department of Hematologic Oncology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Biol Blood Marrow Transplant 15:851-5. 2009
    ..9%. Late relapse (P = .039) and late NRM (P = .008) occurred at higher rates in patients beyond CP at transplantation. There was no plateau in LFS...
  5. doi A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma
    E Copelan
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA
    Bone Marrow Transplant 43:101-5. 2009
    ..There were no adverse consequences of rituximab on CD34+ cell yield, or hematopoietic recovery or immunoglobulin levels after transplantation...
  6. doi Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma
    Brian T Hill
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Leuk Lymphoma 52:986-93. 2011
    ..001). These findings suggest that alternative mobilizing strategies prior to ASCT are needed for patients with mantle cell lymphoma who have received hyper-CVAD...
  7. doi Elevated ferritin is associated with relapse after autologous hematopoietic stem cell transplantation for lymphoma
    Anuj Mahindra
    Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Biol Blood Marrow Transplant 14:1239-44. 2008
    ..Our results indicate the need for studies designed to correlate an elevated ferritin with iron overload and to analyze the benefit of strategies to reduce the extent of iron overload...
  8. doi The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls
    Brian T Hill
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute Quantitative Health Sciences, Cleveland Clinic Lerner Research Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Br J Haematol 152:561-9. 2011
    ..After ASCT, surviving patients have significantly increased risk mortality rates relative to the general population and this excess risk persists over time...
  9. doi Race and intensity of post-remission therapy in acute myeloid leukemia
    Anna K Brady
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
    Leuk Res 35:346-50. 2011
    ..In many cancers, including AML, blacks have poorer overall survival. We investigated whether differences in post-remission therapy (PRT) were a contributing factor...
  10. doi Nonmyeloablative second transplants are associated with lower nonrelapse mortality and superior survival than myeloablative second transplants
    Brian T Hill
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Biol Blood Marrow Transplant 16:1738-46. 2010
    ..NMA second transplants were associated with substantially less NRM and despite a higher incidence of relapse, significantly improved survival compared to MA second transplants...
  11. doi Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres
    Stephen D Smith
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
    Br J Haematol 153:358-63. 2011
    ..Patients with these additional risk factors are best suited for clinical trials investigating novel salvage regimens and post-transplant maintenance strategies...
  12. doi Predicting hematopoietic stem cell mobilization failure in patients with multiple myeloma: a simple method using day 1 CD34+ cell yield
    Hien K Duong
    Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    J Clin Apher 26:111-5. 2011
    ..Patients who collect ≤ 0.70 × 10(6) CD34+ cells/kg on day 1 could be considered for treatment modifications to improve CD34+ collection, such as early administration of plerixafor or large volume apheresis...
  13. doi Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia
    Di Sun
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Am J Hematol 87:957-60. 2012
    ..These data suggest that ALC can be used in combination with other prognostic features to better predict outcome and that targeting the immune system to improve ALC may be a worthwhile strategy in ALL...
  14. ncbi Cytomegalovirus reactivation after matched sibling donor reduced-intensity conditioning allogeneic hematopoietic stem cell transplant correlates with donor killer immunoglobulin-like receptor genotype
    Ronald M Sobecks
    Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland, OH, USA
    Exp Clin Transplant 9:7-13. 2011
    ..This study sought to assess whether donor inhibitory or activating killer immunoglobulin-like receptor genotypes may influence post-transplant cytomegalovirus reactivation in transplant recipients...
  15. doi Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in acute myeloid leukemia
    Anna Brady
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Eur J Haematol 89:288-93. 2012
    ..Constitutive activation of STAT5 (by phosphorylation) has been identified in a number of malignancies, including acute myeloid leukemia (AML)...
  16. doi Defining incidence, risk factors, and impact on survival of central line-associated blood stream infections following hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome
    Joshua Lukenbill
    Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland, OH, USA
    Biol Blood Marrow Transplant 19:720-4. 2013
    ..We propose the MCLABSI definition to replace the OCLABSI definition, given its greater precision for identifying preventable infection in HCT patients...
  17. ncbi Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation
    Anuj Mahindra
    Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
    Br J Haematol 146:310-6. 2009
    ..The association of ferritin with iron overload and its influence on HCT outcomes requires further prospective validation...
  18. ncbi A prognostic scoring system for adult patients less than 60 years of age with acute lymphoblastic leukemia in first relapse
    Anjali Advani
    Taussig Cancer Center, The Cleveland Clinic, Cleveland, OH 44195, USA
    Leuk Lymphoma 50:1126-31. 2009
    ..Patients with a prognostic score of greater than 1 have a poor prognosis, even with BMT, and should be considered for treatment with innovative approaches such as Phase 1 clinical trials...
  19. pmc Allogeneic hematopoietic cell transplant for prolymphocytic leukemia
    Matt E Kalaycio
    Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Biol Blood Marrow Transplant 16:543-7. 2010
    ..Further study of a larger population of patients is needed to determine which patients are more likely to benefit...
  20. ncbi Impact of weekend admissions on quality of care and outcomes in patients with acute myeloid leukemia
    Nelli Bejanyan
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Cancer 116:3614-20. 2010
    ..The authors investigated quality of care and clinical outcomes of newly diagnosed acute myeloid leukemia (AML) patients who were hospitalized on weekends versus weekdays and treated with induction chemotherapy...
  21. pmc Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus
    Zhenbo Hu
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Mol Cancer Ther 9:1536-43. 2010
    ..Using decitabine to deplete DNMT1 after this early repression phase does not impair progressive differentiation...
  22. ncbi Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation
    Sudipto Mukherjee
    Affiliations of authors Leukemia Program SM, RVT, AAA, YS, KP, SH, JPM, BJB, MK, MAS, Department of Radiation Oncology CAR, JPC, MA W, and Department of Solid Tumor Oncology RD, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC EC Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH EAK
    J Natl Cancer Inst 106:djt462. 2014
    ..Exposure to ionizing radiation has been linked to myelodysplastic syndromes (MDS); it is not clear whether therapeutic radiation doses used for prostate cancer pose an increased MDS risk...
  23. pmc Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
    Stephanie J Lee
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 112:3500-7. 2008
    ..Acute graft-versus-host disease rates were similar between IM(+) and IM(-) groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT...